Hyperprogressive Disease In Cervical Small Cell Carcinoma Treated By Immune Checkpoint Inhibitor

A new progression pattern, hyperprogressive disease (HPD), has been recently acknowledged in cancer patients accepted immune checkpoint inhibitors (ICIs). We report a unique case of cervical small cell carcinoma which showed primary resistance to pembrolizumab and was with a rapid radiological progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Zihan, Chen, Liying, Zheng, Linpeng, Yang, Qiao, Chen, Mingjing, Wang, Jianmin, Zhu, Guangkuo, Chen, Zhengtang, Sun, Jianguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826182/
https://www.ncbi.nlm.nih.gov/pubmed/31802899
http://dx.doi.org/10.2147/OTT.S213436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826182/
https://www.ncbi.nlm.nih.gov/pubmed/31802899
http://dx.doi.org/10.2147/OTT.S213436

Ejemplares similares